IL322667A - Ardepitinib for intravesical administration for use in the treatment of bladder cancer - Google Patents
Ardepitinib for intravesical administration for use in the treatment of bladder cancerInfo
- Publication number
- IL322667A IL322667A IL322667A IL32266725A IL322667A IL 322667 A IL322667 A IL 322667A IL 322667 A IL322667 A IL 322667A IL 32266725 A IL32266725 A IL 32266725A IL 322667 A IL322667 A IL 322667A
- Authority
- IL
- Israel
- Prior art keywords
- erdafitinib
- use according
- patient
- pharmaceutical composition
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/007—Injectors for solid bodies, e.g. suppositories
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/08—Tubes; Storage means specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1085—Bladder
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363484591P | 2023-02-13 | 2023-02-13 | |
| US202463623193P | 2024-01-19 | 2024-01-19 | |
| PCT/US2024/015572 WO2024173377A1 (fr) | 2023-02-13 | 2024-02-13 | Erdafitinib pour administration intravésicale destiné à être utilisé dans le traitement du cancer de la vessie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL322667A true IL322667A (en) | 2025-10-01 |
Family
ID=90368308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322667A IL322667A (en) | 2023-02-13 | 2024-02-13 | Ardepitinib for intravesical administration for use in the treatment of bladder cancer |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4665342A1 (fr) |
| JP (1) | JP2026511334A (fr) |
| KR (1) | KR20250143348A (fr) |
| CN (1) | CN120731076A (fr) |
| AU (1) | AU2024220896A1 (fr) |
| IL (1) | IL322667A (fr) |
| MX (1) | MX2025009446A (fr) |
| TW (1) | TW202448472A (fr) |
| WO (1) | WO2024173377A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025059602A1 (fr) * | 2023-09-14 | 2025-03-20 | Taris Biomedical Llc | Méthodes de traitement du cancer de la vessie à l'aide d'une administration intravésicale d'erdafitinib |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2744096C (fr) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate |
| US7772872B2 (en) | 2008-09-08 | 2010-08-10 | Altera Corporation | Multi-row block supporting row level redundancy in a PLD |
| CA2765630C (fr) | 2009-06-26 | 2016-07-05 | Taris Biomedical, Inc. | Comprimes de medicament solides pour dispositifs d'administration de medicament implantables |
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
| AU2010339821B2 (en) | 2009-12-17 | 2015-02-19 | Taris Biomedical Llc | Implantable device with intravesical tolerability and methods of treatment |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| WO2012048114A1 (fr) | 2010-10-06 | 2012-04-12 | Taris Biomedical, Inc. | Systèmes et procédés d'administration de médicament biorésorbables ou rétractables sélectifs dans le temps |
| WO2012048104A1 (fr) | 2010-10-06 | 2012-04-12 | Taris Biomedical, Inc. | Dispositif d'administration de médicament implantable avec composant de rétention dans la vessie |
| ES2637388T3 (es) | 2011-02-04 | 2017-10-13 | Taris Biomedical, Inc. | Dispositivo implantable para la liberación controlada de un fármaco de baja solubilidad |
| PL2968880T3 (pl) | 2013-03-15 | 2025-06-23 | Taris Biomedical Llc | Urządzenia do dostarczania leku ze składnikiem przepuszczalnym dla leku |
| CR20170104A (es) | 2014-09-26 | 2017-05-31 | Janssen Pharmaceutica Nv | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr |
| JO3695B1 (ar) | 2015-02-10 | 2020-08-27 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين) |
| EP4744688A2 (fr) | 2015-04-23 | 2026-05-20 | Janssen Biotech Inc | Dispositifs d'administration de médicament avec composant perméable aux médicaments et procédés |
| EP3946340A1 (fr) | 2019-03-29 | 2022-02-09 | Janssen Pharmaceutica NV | Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial |
| EP3979947A4 (fr) * | 2019-06-10 | 2023-07-12 | Poly-Med Inc. | Procédés, dispositifs et compositions pour une administration locale |
| PH12022552093A1 (en) * | 2020-02-12 | 2023-11-29 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| EP4415692A1 (fr) * | 2021-10-12 | 2024-08-21 | TARIS Biomedical LLC | Formulations d'erdafitinib et systèmes d'administration intravésicale |
| KR20240145513A (ko) * | 2022-02-18 | 2024-10-07 | 타리스 바이오메디컬 엘엘씨 | 에르다피티닙 제형 및 방광내 투여를 위한 삼투성 시스템 |
-
2024
- 2024-02-13 EP EP24713174.1A patent/EP4665342A1/fr active Pending
- 2024-02-13 IL IL322667A patent/IL322667A/en unknown
- 2024-02-13 CN CN202480012234.XA patent/CN120731076A/zh active Pending
- 2024-02-13 AU AU2024220896A patent/AU2024220896A1/en active Pending
- 2024-02-13 JP JP2025545857A patent/JP2026511334A/ja active Pending
- 2024-02-13 WO PCT/US2024/015572 patent/WO2024173377A1/fr not_active Ceased
- 2024-02-13 KR KR1020257030154A patent/KR20250143348A/ko active Pending
- 2024-02-15 TW TW113105384A patent/TW202448472A/zh unknown
-
2025
- 2025-08-12 MX MX2025009446A patent/MX2025009446A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202448472A (zh) | 2024-12-16 |
| KR20250143348A (ko) | 2025-10-01 |
| AU2024220896A1 (en) | 2025-10-02 |
| MX2025009446A (es) | 2025-11-03 |
| CN120731076A (zh) | 2025-09-30 |
| WO2024173377A1 (fr) | 2024-08-22 |
| EP4665342A1 (fr) | 2025-12-24 |
| JP2026511334A (ja) | 2026-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240350485A1 (en) | Erdafitinib formulations and systems for intravesical administration | |
| EP2276465B1 (fr) | Formulation à libération prolongée contenant une cire | |
| US20250041574A1 (en) | Erdafitinib formulations and osmotic systems for intravesical administration | |
| US20030003150A1 (en) | System for osmotic delivery of pharmaceutically active agents | |
| JP6068803B2 (ja) | 癌治療用組成物及び癌治療方法 | |
| JP7391009B2 (ja) | 腫瘍転移を処置する方法 | |
| US10322096B2 (en) | Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms | |
| JP2024009888A (ja) | ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法 | |
| JP2025507590A5 (fr) | ||
| AU2024220896A1 (en) | Erdafitinib for intravesical administration for use in the treatment of bladder cancer | |
| WO2007010847A1 (fr) | Préparation à libération prolongée | |
| CN118382431A (zh) | 用于膀胱内施用的厄达替尼制剂和系统 | |
| AU2024340600A1 (en) | Methods of treating bladder cancer using intravesical administration of erdafitinib | |
| WO2024173716A1 (fr) | Erdafitinib pour administration intravésicale destiné à être utilisé dans le traitement du cancer de la vessie | |
| EP3769764A1 (fr) | Composition pharmaceutique et son procédé de préparation et ses utilisations | |
| Patil | Formulation and Evaluation Biodegradable Polymer Based Implants as Anticancer Drug Delivery Systems | |
| EA045084B1 (ru) | Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина | |
| HK1147192B (en) | Extended release formulation containing a wax |